## 1 Title page:

- 2 Title:
- 3 Fear of COVID-19 after vaccination dissemination and its relationship with multidimensional
- 4 health literacy among patients on maintenance haemodialysis
- 5
- 6 Authors:
- 7 Atsuro Kawaji<sup>1#</sup>, Ryohei Inanaga<sup>2, 3#</sup>, Mamiko Ukai<sup>4#</sup>, Tetsuro Aita<sup>2, 5</sup>, Yusuke Kanakubo<sup>4, 6</sup>,
- 8 Takumi Toishi<sup>1</sup>, Masatoshi Matsunami<sup>1, 2</sup>, Tatsunori Toida<sup>2, 7</sup>, Yu Munakata<sup>8, 9</sup>, Tadao
- 9 Okada<sup>4</sup>, Tomo Suzuki<sup>1, 2</sup>, Noriaki Kurita<sup>2, 10</sup>
- 10 <sup>#</sup>AK, RI, and MU contributed equally.
- 11

# 12 Affiliations:

- <sup>1</sup>Department of Nephrology, Kameda Medical Center, Chiba, Japan
- <sup>2</sup> Department of Clinical Epidemiology, Graduate School of Medicine, Fukushima Medical
- 15 University, Fukushima, Japan
- <sup>3</sup> Department of Nephrology, Shin-Yurigaoka General Hospital, Kanagawa, Japan
- <sup>4</sup> Tessyoukai Kameda Family Clinic Tateyama, Chiba, Japan
- <sup>5</sup> Department of General Internal Medicine, Fukushima Medical University Hospital,
- 19 Fukushima, Japan
- <sup>6</sup> Division of Clinical Epidemiology, Research Center for Medical Sciences, The Jikei University
   School of Medicine, Tokyo, Japan
- <sup>7</sup> School of Pharmaceutical Sciences, Kyushu University of Health and Welfare, Miyazaki,
- 23 Japan
- 24 <sup>8</sup> Chikuseikai Munakata Clinic, Tokyo, Japan
- 25 <sup>9</sup> Munakata Clinic, Chiba, Japan
- <sup>10</sup> Department of Innovative Research and Education for Clinicians and Trainees (DiRECT),
- 27 Fukushima Medical University Hospital, Fukushima, Japan

- 29 Correspondence to:
- 30 Tomo Suzuki, MD, PhD
- 31 Department of Nephrology
- 32 Kameda Medical Center

- 1 929, Higashicho, Kamogawa, Chiba 296-8602, Japan
- 2 Phone: +81-4-7092-2211
- 3 Email: suzuki.tomo@kameda.jp
- 4 ORCID: 0000-0001-5536-1741
- 5 X handle: km\_nephrology
- 6
- 7 Word count: 2699 words
- 8 Number of figures, tables, boxes, references: 4
- 9 **Running head:** health literacy and COVID-19 fear

#### 1 Abstract

#### 2 Background and hypothesis.

- 3 The increased anxiety owing to the COVID-19 pandemic has been suggested to contribute to
- 4 unhealthy lifestyles and depression in patients undergoing haemodialysis (HD). Therefore,
- 5 this study aimed to evaluate the degree of fear of COVID-19 after vaccination dissemination
- 6 and the independent impact of high-order health literacy (HL) on fear, which have not been
- 7 adequately investigated.

#### 8 Methods.

- 9 This multicentre cross-sectional study, conducted in 2022, after the widespread availability
- 10 of the COVID-19 vaccination in Japan, included adults undergoing in-centre HD.
- 11 Multidimensional HL was measured using the 14-item Functional, Communicative, and
- 12 Critical Health Literacy Scale. Fear of COVID-19 was measured using the 7-item Japanese
- 13 version of the Fear of COVID-19 Scale. COVID-19 fear scores in patients with HD were
- compared with scores of adults in April 2020 (the beginning of the pandemic) using an
- 15 unpaired t-test. The association between multidimensional HL and COVID-19 fear scores
- 16 was estimated using a multivariable-adjusted general linear model.

#### 17 Results.

18 A total of 446 patients were analysed, of whom 431 (97%) and nine (2%) received three and

- 19 two doses of vaccination, respectively. Their COVID-19 fear scores were significantly lower
- than those of the general population at the beginning of the pandemic (p < 0.001; mean
- difference -4.4 [95% confidence interval (CI): -5.1 -3.7]; standardised effect size [ES] 0.77).
- Higher functional HL was associated with less fear (per 1-pt higher: -2.8 [95% CI: -1.7 -0.3];
- standardised ES -0.51), whereas higher critical HL was associated with greater fear (per 1-pt

1 higher: 3.2 [95% CI: 0.7 – 3.0]; standardised ES 0.80). Communicative HL was not associat	ted
---	-----

- 2 with fear.
- 3 Conclusion.
- 4 Patients' fear of low-functional HL, despite widespread vaccination, can be reduced by
- 5 providing health information in an easy-to-understand manner. Thus, the fear of sceptics
- 6 owing to excessive critical HL and honest explanations by healthcare providers may be
- 7 important.
- 8

#### 9 Key learning points

- 10 What was known:
- 11 Heightened anxiety stemming from the COVID-19 pandemic exacerbates unhealthy
- 12 lifestyles and depression, particularly in patients undergoing haemodialysis.
- 13 Health literacy plays a crucial role in individuals with kidney disease and may mitigate
- 14 anxiety.
- 15 Comprehensive data on whether multidimensional health literacy (functional, critical, and
- 16 communicative) independently correlates with fear of COVID-19, particularly in the context
- 17 of patients undergoing haemodialysis are lacking.
- 18 This study adds:
- 19 COVID-19 fear scores were notably lower in patients undergoing haemodialysis who
- 20 received the COVID-19 vaccination than in the general population at the onset of the

21 pandemic.

- 22 Elevated functional health literacy correlated with reduced fear, whereas higher critical
- 23 health literacy was linked to increased fear.

### 1 **Potential impact:**

- 2 Fear among individuals with low functional health literacy can be alleviated by delivering
- 3 health information in a clear and accessible manner, whereas transparent and honest
- 4 communication from healthcare providers is crucial for patients with heightened fear owing
- 5 to critical health literacy, who may be sceptical of accurate information.
- 6
- 7 **Keywords:** COVID-19, health literacy, anxiety, haemodialysis, end-stage kidney disease.

### 1 Introduction

2	Fear of the COVID-19 pandemic causes considerable anxiety disorders, especially
3	among patients with chronic kidney disease (CKD) who are at high risk of severe disease. In
4	particular, patients undergoing haemodialysis who are required to share a specific space
5	and spent time in a dialysis unit would have felt strong fear during epidemic periods.
6	Although strong fear and anxiety may have increased adherence to vaccination and wearing
7	of masks in public places, they have also been suggested to have contributed to unhealthy
8	lifestyle habits, weight gain, isolation, and depression among patients with CKD (1,2).
9	Considering the potentially increased risk of all-cause mortality and 1-year hospitalisation
10	rates associated with anxiety symptoms (3), the identification of related factors and
11	implementation of measures to mitigate fear is clinically important. Health literacy (HL), or
12	the ability to understand, discern, or use appropriate information, may help mitigate anxiety
13	because patients with CKD are likely to be confused by inconsistent information about
14	COVID-19 (2). Consequently, HL was viewed as a social vaccine that empowered people to
15	protect their own and high-risk populations' health during the COVID-19 pandemic (4).
16	Given that many patients with CKD have low HL (5), examining the impact of HL on fear of
17	COVID-19 is important; however, it remains poorly studied.
18	Although one study showed that low HL was associated with high anxiety among
19	patients with preserved CKD (1), only "conventional" HL was assessed. Recently, however,
20	the importance of assessing multidimensional HL has increased (6,7). That is, in addition to
21	the most basic functional HL, such as reading and writing, communicative HL (i.e., the ability
22	to extract information, infer meaning, and apply information to changing situations) and

critical HL (i.e., the ability to critically analyse information and control current situations) are

1	also gaining attention (6). One small study showed that higher levels of each of these
2	multidimensional HL dimensions correlated with lower levels of COVID-19 anxiety among
3	patients undergoing haemodialysis. However, the study failed to examine how individual
4	dimensions independently affected anxiety about COVID-19, even though each of the HL
5	dimensions was correlate with the others (8). Therefore, identifying the dimensions of HL
6	that independently influence the fear of COVID-19 in patients undergoing haemodialysis
7	would be useful in developing support tailored to their individual health literacy.
8	Furthermore, the potential to identify and address patients with excessive fear persists
9	despite the spread of effective measures against COVID-19, such as vaccines.
10	Therefore, we aimed to quantify the degree of fear of COVID-19 among patients
11	undergoing maintenance haemodialysis after vaccine dissemination and evaluate whether
12	multidimensional HL (functional, critical, and communicative) was independently associated
13	with fear of COVID-19.
14	
15	Materials and Methods
16	Study Design and Participants
17	This multicentre cross-sectional study was conducted at six medical institutions
18	providing outpatient haemodialysis: Kameda Medical Center (Chiba), Kameda Family Clinic
19	Tateyama (Chiba), Awa Regional Medical Center (Chiba), Munakata Clinic (Chiba),

20 Chikuseikai Munakata Clinic (Tokyo), and Shinyurigaoka General Hospital (Kanagawa). The

- 21 participants were adult patients with End-stage kidney disease (ESKD) who regularly visited
- 22 the participating facilities and received either haemodialysis or a hybrid treatment of
- 23 haemodialysis and peritoneal dialysis. Patients deemed by medical staff as unable to

1	respond to the study questionnaire by themselves were excluded from the study. A paper-
2	based questionnaire was distributed at each facility, and the participants were asked to
3	complete the questionnaire at home and return it to the medical staff without identifying
4	the content. The respondents were provided with a 500-yen gift card as an incentive. In
5	addition, the attending physician extracted dialysis-related patient data from medical
6	records. Data were collected between June 2022 and February 2023, after the spread of the
7	COVID-19 vaccine in Japan. This study was conducted in accordance with the Declaration of
8	Helsinki and approved by the Institutional Review Board of Fukushima Medical University
9	(approval number: ippan2021-292). All participants were provided with information about
10	the study in advance, and written informed consent was obtained from all participants.
11	
12	Measures
13	Outcome: Fear of COVID-19
14	The main outcome, fear of COVID-19, was measured using the Japanese version of
15	the COVID-19 Scale (9,10). This scale consists of seven items and responses are scored on a

16 5-point Likert scale ranging from 1 (strongly disagree) to 5 (strongly agree). The total score

17 was calculated by adding the scores for each item (7–35 points), with a higher score

18 indicating a stronger fear of COVID-19. The Japanese version of the scale has been validated

19 in the general population and has been confirmed to have internal consistency reliability ( $\alpha$ 

20 = 0.87) and validity (9).

21

### 1 Exposure: multidimensional health literacy

2	The main exposure, multidimensional HL, was measured using the Functional,
3	Communicative, and Critical Health Literacy (FCCHL) scale (11). This self-report scale consists
4	of 14 items and can be scored on three subscales: Functional HL (five items), Communicative
5	HL (five items), and Critical HL (four items). Responses to each item were scored on a four-
6	point Likert scale ranging from 1 (never) to 4 (often). The scores were reversed when
7	functional HL was measured. The mean score of the corresponding items was used as the
8	scale score for each of the three subscales, with higher scores indicating higher HL levels of
9	health literacy. This scale has previously shown high internal consistency for functional,
10	communicative, and critical HL (alpha coefficients of 0.84, 0.77, and 0.65, respectively) in
11	Japanese patients with type 2 diabetes, demonstrating its construct validity and reliability
12	(11).

13

#### 14 Measurement of Covariates

Based on the literature and expert knowledge, potential confounding factors that could affect health literacy and fear of COVID-19 were identified. The covariates included age, sex, duration of dialysis, smoking history, educational level, household income, and comorbidities. Comorbidities were scored based on the modified Charlson Comorbidity Index (CCI) for patients undergoing dialysis (12,13).

20

21

#### 1 Statistical Analyses

2	Statistical analyses were performed using Stata/SE, version 17 (StataCorp, College
3	Station, TX, USA). Patient characteristics are presented as median and interquartile range
4	(IQR) for continuous variables and as frequencies and percentages for categorical variables.
5	Differences between the fear of COVID-19 scores in the present study and those of 450
6	Japanese adults in April 2020 (i.e. the beginning of the COVID-19 pandemic) reported in the
7	development paper were compared using an unpaired t-test (9). The association between
8	the aforementioned covariates and each domain of multidimensional HL was estimated
9	using general linear models. Subsequently, the association between multidimensional HL
10	and fear of COVID-19 was estimated using a general linear model. The above-mentioned
11	covariates were adjusted. All models were estimated using robust standard errors to
12	address heteroscedasticity. We assumed that the data analysed were missing at random,
13	and imputed the missing data using multiple imputations with chained equations to perform
14	20 imputations (14). A two-sided significance level of p < 0.05 was used for each analysis.
15	
16	Results
17	Study flow and patient characteristics
18	Among the 651 patients undergoing haemodialysis at six facilities, 484 (74.3%)
19	participated in the study. After excluding 38 cases with missing data on the fear of COVID-
20	19, 446 cases were analysed. Patient characteristics are shown in Table 1. The median age
21	of the patients was 69 years (IQR 63–78), and 157 (35.2%) patients were women. A total of
22	61.6% patients had graduated from high school and 79.8% patients had a household income

of < 5 million yen. A total of 431 (96%) and nine (2%) patients received three and two doses

1	of the COVID-19 vaccine, respectively. The median scores for the functional, communicative,
2	and critical HL subdomains were 3.2 (IQR 2.6–3.8), 2.8 (IQR 2.2–3.2), and 2.5 (IQR 2.0–3.0),
3	respectively.
4	
5	Comparison of the fear of COVID-19 between study participants and the general population
6	in the early phase of the pandemic
7	The mean and standard deviation of the fear of COVID-19 scores among the
8	participants was 16.9 and 5.7 points, which was significantly lower than the score of the
9	general population in the early phase of the pandemic (p < 0.001; mean difference -4.4 [95%
10	confidence interval (CI): -5.1 to -3.7]; standardised effect size (ES) 0.77). (9) (Figure 1):
11	
12	Association between HL subdomains and patient characteristics
13	Table 2 shows the association between the HL subdomains and covariates.
14	Functional HL was positively associated with dialysis duration (per 1 year higher: 0.01 [95%
15	CI: 0.002 – 0.02]) and education (especially high school, university, and other) (vs. junior
16	high school or lower: 0.37 [95% CI: 0.16 – 0.58], 0.64 [95% CI: 0.39 – 0.89], 0.87 [95% CI:
17	0.27 – 1.46]) but negatively associated with comorbidity score (per 1 point higher: -0.66
18	[95% CI: -0.11 – -0.02], respectively). Communicative HL was positively associated with
19	educational level (especially university graduate, high school, other) (vs. junior high school
20	or lower: 0.50 [95% CI: 0.27 – 0.74], 0.17 [95% CI: 0.0004 – 0.34], 0.63 [95% CI: 0.07 – 1.12],
21	respectively) and was negatively associated with age (per 1 year higher: -0.07 [95% CI: -0.12
22	– -0.002]) and comorbidity score (per 1 point higher: -0.05 [95% CI: -0.08 – -0.01]). Critical

1	HL was positively associated with educational level (especially university graduate, other) (vs.
2	junior high school or lower: 0.46 [95% CI: 0.21 – 0.71], 0.58 [95% CI: 0.07 – 2.20]) but
3	negatively associated with comorbidity score (per 1-point higher: -0.04 [95% CI: -0.07 – -
4	0.006]).
5	
6	Association between fear of COVID-19 and multidimensional HL
7	Table 3 shows the associations among fear of COVID-19 and HL subdomains, and
8	covariates. Fear of COVID-19 was negatively associated with functional HL (per 1-point
9	higher: -0.99 [95% CI: -1.72 – -0.26]) and household income (especially > 5 million yen – < 10
10	million yen) (reference: < 1 million yen: -3.01 [95% Cl: -5.41 – -0.61]). In contrast, higher
11	critical HL (per 1-point higher: 1.85 [95% CI: 0.74 – 2.97]) and women (vs. men; 1.98 [95% CI:
12	0.73 – 3.23]) were positively associated with fear of COVID-19. Communicative HL was not
13	associated with fear.
14	
15	Discussion
16	
17	Our results indicated that fear of COVID-19 among adult Japanese patients on
18	haemodialysis was significantly lower than that of the general population in the early phase
19	of the pandemic after the widespread distribution of the COVID-19 vaccine. However, the
20	findings that low functional HL and high critical HL were associated with increased fear of
21	COVID-19 highlight the need for measures tailored to individual HL even after the
22	dissemination of the vaccine.

1	Although previous research on the level of anxiety after the widespread use of
2	COVID-19 vaccines among patients on dialysis is scarce, findings on the relationship
3	between multidimensional HL and COVID-19-related anxiety are similar to those found in
4	the non-dialysis population. Older age and a history of diabetes, heart disease, or lung
5	disease were associated with an increased likelihood of having anxiety related to COVID-19
6	in a study conducted on the general population in the UK during the early period of the
7	COVID-19 pandemic (March 2020) (15). There are a few possible reasons why our patients
8	with the same serious illness as those mentioned above were less anxious about COVID-19
9	than the general population before the pandemic. First, the high vaccination rate (98%) and
10	alleviation of uncertainty regarding the pathogenesis and prevention of COVID-19 in the
11	early phase of the pandemic may have reduced anxiety in our study participants. Similarly,
12	although patients on haemodialysis were more anxious than those on peritoneal dialysis
13	before the vaccination programme in a study comparing patients on haemodialysis and
14	peritoneal dialysis in the Netherlands, no such difference was observed after the
15	programme (16). However, as noted in a previous synthesised qualitative study, the
16	uncertainty about healthcare experienced during the pandemic, such as the disruption of
17	care, confusion owing to a lack of reliable information, and scepticism about vaccines,
18	undoubtedly contributed to anxiety among patients on dialysis (2).
19	Another explanation is that the mental health of patients on dialysis was resilient to
20	or unaffected by the COVID-19 pandemic. This is consistent with a previous study wherein
21	mental health was not affected during the pandemic in Dutch patients with CKD or in those
22	on dialysis who did not develop COVID-19 (17). Additionally, the limited impact of social

23 distancing measures compared to that in the general population (18), the strengthening of

1 family ties, and the sense of safety towards healthcare institutions owing to strict

2 preventative measures (2,18) may have helped alleviate anxiety.

3	A U.S. study on fear of COVID-19 linked to low health literacy among patients with
4	non-dialysis-dependent CKD only examined functional HL (1). Whereas, all three types of
5	HLs (functional, communicative, and critical) showed a negative correlation (i.e. low health
6	literacy was associated with a high fear of COVID-19) with fear of COVID-19 among patients
7	on haemodialysis (8); however, this study did not adjust for confounding factors. In contrast,
8	as shown in the current study, differences owing to confounding factors such as age, sex,
9	education history, and comorbidities were not addressed. Additionally, although our finding
10	of higher critical HL along with a greater fear of COVID-19 contradicts the Korean study; it is
11	consistent with a survey of the Japanese general population (19). The fear of COVID-19
12	among groups with high HL in that study was also directed toward government and social
13	policies. (19) Moreover, higher critical HL has been suggested to be associated with worse
14	medication adherence (particularly in terms of behavioural aspects) among patients on
15	haemodialysis, mainly owing to a loss of trust in physicians (7). Additionally, patients with
16	high critical HL may have gathered too much information about the pandemic resulting in
17	unnecessary scepticism about the gathered information, including the best information
18	provided by the government and physicians at the time.

This study has several clinical implications for dialysis providers. First, communicating the correct medical information about COVID-19 using plain language in an easy-to-understand manner is important for patients with low functional HL. For example, the term "droplet infection" as a medical term is difficult to understand, however explaining "it is an infection that occurs when the virus is scattered from the mouth when talking" is easier to

1 understand. In addition, providing visual aids to communicate recommended preventive 2 measures, such as wearing masks, will encourage preventive behaviours. Second, for 3 patients with excessively high critical HL, we should consider the positive aspect that 4 caution provides opportunities for appropriate preventive actions. Therefore, dialysis physicians must support patients by identifying misleading information, false claims, and 5 6 fake news (4). For example, although measures against COVID-19 from reliable information 7 sources (e.g. government or medical institutions) are likely to be beneficial, a claim by a 8 Japanese academic virologist about the risk of miscarriage owing to COVID-19 vaccination 9 via social media may have been difficult to discern as false without comparing different 10 sources or checking for evidence of its origin. Finally, doctors need to be aware of the kinds 11 of patients who are likely to have low functional or high critical HL. In this study, low 12 functional HL was associated with a high number of comorbidities, low educational level, 13 and shorter dialysis duration. In contrast, high critical HL was associated with younger age, low number of comorbidities, and high education level. Thus, addressing individual HL is 14 15 important because it is affected by several common factors such as education level and 16 comorbidities.

17 The strengths of this study include the relatively high participation rate and multi-18 centre design, making the results highly generalisable. In addition, we analysed the 19 association between multidimensional HL and fear of COVID-19 after adjusting for relevant 20 confounding factors. Nonetheless, this study has some limitations. First, although this study 21 measured general HL, it did not directly assess HL related to COVID-19. Second, because this 22 was a cross-sectional study, a possibility of reverse causation exists. For example, it is 23 possible that patients were fearful of COVID-19 and, therefore, were sceptical of health 24 information, including correct information. Third, because most patients had already been

vaccinated, we were unable to compare their HL or fear of COVID-19 with those who had
 not been vaccinated.

3	In conclusion, fear of COVID-19 among adult Japanese patients undergoing
4	haemodialysis after the widespread COVID-19 vaccine was lower than that in the general
5	population at the beginning of the pandemic. The fear of COVID-19 in patients with low-
6	functional HL can be reduced by providing health information in an easy-to-understand
7	manner. Consequently, honest explanations by healthcare providers may be important for
8	patients with scepticism about correcting information and a strong fear of excessive critical
9	HL. This study is novel in that it investigated the degree of fear of COVID-19 following
10	vaccination and the independent influence of multidimensional HL on fear. An
11	understanding of individual HL may help them to provide appropriate anxiety reduction
12	measures for future pandemics.
13	
14	Data availability statement:
15	The datasets generated and/or analysed in the current study are available from the
16	corresponding author upon reasonable request.
17	
18	Acknowledgements:
19	The authors greatly thank the following researchers, research assistants, and medical staff
20	members for their assistance in collecting the questionnaire-based and clinical information
21	used in this study: Ms. Aki Tairaku (Shin-Yurigaoka General Hospital, Kawasaki-City,
22	Kanagawa); Ms. Takako Saruwatari and Ms. Akiko Kamimura (Kyushu University of Health
23	and Welfare, Nobeoka-City, Miyazaki); Tetuo Ueki, MD, Akio Munakata, MD, Yoshihiko

1	Watanabe, MD (Munakata Clinic, Mobara-City, Chiba); Ms. Yayoi Takanashi, Reiji Masaki,
2	NP, Tomohiko Inoue, MD, Shinnosuke Sugihara, MD, Kanako Nagaoka, MD and Hiroshi Kuji,
3	MD (Kameda Medical Center, Kamogawa-City, Chiba); Kenji Yamaguchi, MD (Awa Regional
4	Medical Center, Tateyama-City, Chiba); Ms. Miyuki Sato (Fukushima Medical University
5	Hospital, Fukushima-City, Fukushima).
6	
7	Funding:
8	This study was supported by JSPS KAKENHI (grant numbers JP19KT0021 and JP24K14750).
9	Authors' contributions:
10	Research idea and study design: AK, MU, and NK; data acquisition: AK, RI, MU, YK, T. Toishi,
11	MM, TO, YM, and TS; data analysis/interpretation: AK, RI, MU, TS, and NK; statistical
12	analysis: MU, TS, and NK; supervision or mentorship: TO, TS, and NK. Each author
13	contributed important intellectual content during manuscript drafting or revision, agreed to
14	be personally accountable for the individual's contributions, and ensured that questions on
15	the accuracy or integrity of any portion of the work, even one in which the author was not
16	directly involved, were appropriately investigated and resolved, including documentation in
17	the literature, if appropriate.
18	
19	Conflict of interest statement:

The RI received payments for speaking from Astellas Pharma, Inc., Novartis Pharma K.K., and
Otsuka Pharmaceuticals. T. Toida received consulting fees from Astellas Pharma Inc. and
payments and educational events from Torii Pharmaceutical Co., Ltd., Ono Pharmaceutical
Co., Ltd., Kyowa Kirin Co., Ltd., AstraZeneca K.K., and Nobelpharma Co., Ltd. T. Toishi

1	received payments for speaking and educational events from Otsuka Pharmaceuticals. YK
2	has ownership interest in Takeda Pharmaceutical Co., Ltd. MM received payments for
3	speaking and educational events from Astellas Pharma, Inc. and Baxter Co., Ltd. TS has
4	received payment for speaking and educational events from Astellas Pharma Inc.,
5	AstraZeneca K.K, Baxter Co., Ltd., Bayer Yakuhin., Ltd., Bristol-Myers Squibb Co., CureApp,
6	Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., Janssen
7	Pharmaceutical K.K, Kaneka Medix Corp, Kissei Pharmaceutical Co., Ltd., Kowa Co., Ltd.,
8	Kyowa Kirin Co., Ltd, Mochida Pharmaceutical Co., Ltd., Nobelpharma Co., Ltd, Novartis
9	Pharma K.K., Novo Nordisk Pharma., Ltd., Ono Pharmaceutical Co., Ltd., Otsuka
10	Pharmaceutical, Terumo Corp, and Torii Pharmaceutical Co., Ltd. NK received grants from
11	the Japan Society for the Promotion of Science, consulting fees from GlaxoSmithKline K.K.,
12	and payments for speaking and educational events from Taisho Pharmaceutical Co. Ltd., Eisai
13	Co. Ltd., UCB Japan K.K., and Selista Corporation. The remaining authors have no conflicts to
14	disclose.
15	

## 16 **References:**

Dorans KS, et al. Associations of Anxiety during the COVID-19 Pandemic with Patient
 Characteristics and Behaviors in CKD Patients: Findings from the Chronic Renal Insufficiency
 Cohort (CRIC) Study. *Kidney360* 2022; **3**: 1341–9.

20 2. Natale P, et al. The Impact of the COVID-19 Pandemic on Patients With CKD:

21 Systematic Review of Qualitative Studies. *Am J Kidney Dis* 2023; **82**: 395–409.e1.

22 3. Schouten RW, et al. Anxiety Symptoms, Mortality, and Hospitalization in Patients

Receiving Maintenance Dialysis: A Cohort Study. *Am J Kidney Dis* 2019; **74**: 158–66.

Okan O, et al. Health literacy as a social vaccine in the COVID-19 pandemic. *Health Promot Int* 2023; **38**: daab197.

3 5. Taylor DM, et al. A Systematic Review of the Prevalence and Associations of Limited Health Literacy in CKD. Clin J Am Soc Nephrol. 2017; 12: 1070-84. 4 6. 5 Nutbeam D. Health literacy as a public health goal: a challenge for contemporary 6 health education and communication strategies into the 21st century. *Health Promot Int* 2000; **15**: 259–67. 7 8 7. Inanaga R, et al. Trust, Multidimensional Health Literacy, and Medication Adherence 9 among Patients Undergoing Long-Term Hemodialysis. Clin J Am Soc Nephrol 2024; 19: 463-10 71. 8. Yoon IJ, Lee SJ. Health Literacy and Anxiety Among Hemodialysis Patients During the 11 12 Coronavirus Disease Pandemic. *Psychol Res Behav Manag* 2023; **16**: 1051–61. 9. 13 Wakashima K, et al. The Japanese version of the Fear of COVID-19 scale: Reliability, validity, and relation to coping behavior. *PloS one* 2020; **15**: e0241958. 14 15 10. Ahorsu DK, Lin et al. The fear of COVID-19 scale: Development and initial validation. nt J Ment Health Addict 2022; 20: 1537-45. 16 Ishikawa H, Takeuchi T, Yano E. Measuring functional, communicative, and critical 17 11. health literacy among diabetic patients. *Diabetes care* 2008; **31**: 874–9. 18

19 12. Hemmelgarn BR, et al. Adapting the Charlson Comorbidity Index for use in patients
20 with ESRD. *Am J Kidney Dis* 2003; **42**: 125–32.

- 1 13. Kanakubo Y, et al. Association between person-centred care quality and advance
- 2 care planning participation in haemodialysis. BMJ Suppor Palliat Care 2024
- 3 http://dx.doi.org/10.1136/spcare-2024-004831
- 4 14. Austin PC, et al. Missing Data in Clinical Research: A Tutorial on Multiple Imputation.
- 5 *Can J Cardiol* 2021; **37**: 1322–31.
- 6 15. Shevlin M, et al. Anxiety, depression, traumatic stress and COVID-19-related anxiety
- in the UK general population during the COVID-19 pandemic. *BJPsych Open* 2020; **6**: e125.
- 8 16. Bouwmans P, et al. Differences in mental health status during the COVID-19
- 9 pandemic between patients undergoing in-center hemodialysis and peritoneal dialysis. J
- 10 *Nephrol* 2023; **36**: 2037–46.
- 11 17. Hilbrands LB. The COVID-19 pandemic and mental health outcomes in CKD patients.
- 12 Nephrol Dial Transplant 2023; **38**: 2673–4.
- 13 18. Bonenkamp AA, et al. The Impact of COVID-19 on the mental health of dialysis
- 14 patients. J Nephrol 2021; 34: 337–44.
- 15 19. Kuroda Y, Goto A, Koriyama C, Suzuki K. Association of health literacy with anxiety
- about COVID-19 under an infectious disease pandemic in Japan. *Health Promot Int* 2023; **38**:
- 17 daac200.

## 1 Tables + table legends:

## 2 Table 1. Patient characteristics<sup>†</sup> (N = 446)

		Missing,
		n
Age, years	69.4 (63.0–78.0)	0
Women, n (%)	157 (35.2)	0
Kidney disease, n (%)		0
Diabetic nephropathy	166 (37.2)	
Chronic glomerulonephritis	102 (22.9)	
Nephrosclerosis	61 (13.7)	
Polycystic kidney disease	14 (3.1)	
Others	68 (15.3)	
Unknown	35 (7.9)	
Dialysis duration, year	5.8 (2.9-10.6)	0
Comorbidities, n (%)		
Cardiovascular disease	187 (42.3)	4
Depression	10 (2.2)	1
Diabetes	192 (43.3)	3
Malignancy	47 (10.6)	1
Leukaemia	2 (0.5)	1
Malignant lymphoma	5 (1.1)	1
Dementia	19 (4.3)	2
Chronic liver disease	25 (5.6)	1
Peptic ulcer	33 (7.4)	0
Chronic lung disease	11 (2.5)	3
Collagen disease	11 (2.5)	2
modified Charlson score, points	1.0 (0–2)	0
Smoking, n (%)		21
Never	232 (54.6)	
Ever	145 (34.1)	
Current	48 (11.3)	
Household income, n (%)		35
< 1,000,000 yen	37 (9.0)	
1,000,000-<5,000,000 yen	291 (70.8)	
5,000,000– < 10,000,000 yen	69 (16.8)	
> 10,000,000 yen	14 (3.4)	
Education level, n (%)		19
Junior high school graduate or less	102 (23.9)	
High school graduate	263 (61.6)	
University/Graduate school graduate	57 (13.3)	
Others	5 (1.2)	
COVID-19 vaccination, n (%)		0
Unvaccinated	1 (0.2)	

Once	5 (1.1)	
Twice	9 (2.0)	
Thrice	431 (96.6)	
Functional HL, per 1-pt higher	3.2 (2.6 <del>–</del> 3.8)	14
Communicative HL, per 1-pt higher	2.8 (2.2 <del>–</del> 3.2)	24
Critical HL, per 1-pt higher	2.5 (2.0–3.0)	13

<sup>†</sup>Continuous variables are summarised as median (interquartile range). Categorical variables

2 are presented as frequencies and proportions (parentheses).

- 3 According to the "Comprehensive Survey of Living Conditions" conducted by the Ministry of
- 4 Health, Labour and Welfare in 2022, the percentages of household income < 1 million yen,
- 5 1–3 million yen, 3–5 million yen, 5–10 million yen, and >10 million yen were 7%, 28%, 23%,
- 6 30%, and 13%, respectively.

# 1 Table 2. Associations of health literacy domains with covariates<sup>†</sup> (N = 446)

	Functional HL		Communicative HL		Critical HL	
	mean difference, point estimate (95%Cl)	P-value	mean difference, point estimate (95%CI)	P-value	mean difference, point estimate (95%CI)	P-value
Age, per 10-yr higher	-0.002 (-0.08 – 0.05)	0.610	-0.07 (-0.12 – -0.002)	0.012	-0.01 (-0.02 – -0.004)	0.001
Women vs. Men	-0.01 (-0.19 <del>-</del> 0.17)	0.904	0.06 (-0.09 <del>-</del> 0.22)	0.429	0.08 (-0.07 <del>-</del> 0.24)	0.303
Smoking						
Never	Reference		Reference		Reference	
Ever	0.09 (-0.09 – 0.27)	0.271	0.09 (-0.08 – 0.27)	0.287	0.01 (-0.16 – 0.18)	0.886
Current	-0.01 (-0.27 – 0.27)	0.271	-0.03 (-0.27 <del>-</del> 0.19)	0.764	0.03 (-0.18 <del>-</del> 0.25)	0.767
Household income						
< 1,000,000 yen	Reference		Reference		Reference	
1,000,000 <del>–</del> < 5,000,000 yen	0.17 (-0.13 – 0.47)	0.266	0.02 (-0.23 <del>-</del> 0.28)	0.862	-0.03 (-0.27 <b>–</b> 0.20)	0.771
5,000,000 <del>-</del> < 10,000,000 yen	0.15 (-0.20 – 0.50)	0.407	-0.06 (-0.35 <b>–</b> 0.24)	0.712	-0.12 (-0.40 <del>-</del> 0.16)	0.384
> 10,000,000 yen	0.28 (-0.21 – 0.78)	0.260	-0.06 (-0.53 <del>-</del> 0.41)	0.813	-0.05 (-0.53 <b>–</b> 0.43)	0.838
Education level						
Junior high school graduate or less	Reference		Reference		Reference	
High school graduate	0.37 (0.16 – 0.58)	< 0.001	0.17 (0.0004 – 0.34)	0.049	0.10 (-0.07 – 0.27)	0.242
University/Graduate school graduate	0.64 (0.39 – 0.89)	< 0.001	0.50 (0.27 – 0.74)	< 0.001	0.46 (0.21 – 0.71)	< 0.001
Others	0.87 (0.27 – 1.46)	0.004	0.63 (0.07 – 1.12)	0.030	0.58 (0.07 – 2.20)	<b>0.02</b> 7
Dialysis duration, per 1-yr higher	0.01 (0.002 – 0.02)	0.013	0.003 (-0.004 – 0.01)	0.389	0.003 (-0.004 – 0.01)	0.373
Modified Charlson score, per 1-pt higher	-0.06 (-0.11 – -0.02)	0.009	-0.05 (-0.08 – -0.01)	0.008	-0.04 (-0.07 – -0.006)	0.021
Depression	-0.15 (-0.64 – 0.33)	0.533	0.12 (-0.28 - 0.51)	0.565	0.35 (-0.04 – 0.74)	0.079

2 Values in bold indicate statistical significance. For each HL domain score, a general linear model was fitted with the inclusion of all the variables listed

3 above. We used a robust standard estimation method. HL, health literacy; CI, confidence interval.

	Corresponding standardised ES	mean difference, point estimate (95%CI)	P-value
Functional HL, per 1-pt higher	-0.18	-0.99 (-1.72 – -0.26)	0.008
Communicative HL, per 1-pt higher	-0.10	-0.59 (-1.69 <del>-</del> 0.51)	0.291
Critical HL, per 1-pt higher	0.34	1.85 (0.74 – 2.97)	0.001
Age, per 10-yr higher	0.006	0.03 (-0.01 – 0.08)	0.160
Women vs. Men	0.37	1.98 (0.73 – 3.23)	0.002
Smoking			
Never		Reference	
Ever	-0.15	-0.79 (-2.06 <del>-</del> 0.47)	0.238
Current	-0.08	-0.42 (-2.22 <del>-</del> 1.39)	0.649
Household income			
< 1,000,000 yen		Reference	
1,000,000- < 5,000,000 yen	-0.25	-1.37 (-3.65 <b>–</b> 0.93)	0.233
5,000,000– < 10,000,000 yen	-0.56	-3.01 (-5.41 – -0.61)	0.014
> 10,000,000 yen	-0.61	-3.29 (-6.49 – 0.10)	0.043
Education level			
Junior high school graduate or less		Reference	
High school graduate	-0.11	-0.57 (-1.97 <del>-</del> 0.85)	0.420
University/Graduate school graduate	-0.30	-1.60 (-3.42 – 0.22)	0.084
Others	0.62	3.36 (-1.55 <del>-</del> 8.28)	0.179
Dialysis duration, per 1-yr higher	0.006	-0.03 (-0.04 – 0.10)	0.367
Modified Charlson score, per 1-pt higher	-0.02	-0.11 (-0.40 <b>-</b> 0.18)	0.450
Depression	0.07	0.39 (-3.03 <del>-</del> 3.81)	0.825

## 1 Table 3. Associations of COVID-19 fear score with health literacy and covariates<sup>†</sup> (N = 446)

2 Values in bold indicate statistical significance. The general linear model was fitted with the

3 inclusion of all the variables listed above. We used a robust standard estimation method. To

4 calculate the corresponding standardised effect size (Cohen d), the point estimate was

5 divided by the SD of the COVID-19 fear scores to calculate the corresponding standardised

6 effect size (Cohen's d). CI, confidence interval; ES, effect size; HL, health literacy.

- 1 Figures + figure legends:
- 2 Figure 1. Comparison of group mean of COVID-19 fear scores
- 3 Using the mean and standard deviation of fear scores for COVID-19 in the present study and
- 4 the corresponding values of the scores from 450 Japanese adults in April 2020 (i.e. at the
- 5 beginning of the COVID-19 outbreak), as reported in a development paper, these groups
- 6 were compared using an unpaired t-test. Error bars indicate 95% confidence intervals. The
- 7 mean difference for this population relative to the Japanese adults was -4.38 points (95%
- 8 confidence interval -5.11 -3.65).

